Abstract
Efficient expression of HIV-1 structural gene involves regulation by viral Rev and Rev-responsive elements (RRE). Messenger RNAs of wild-type HIV-1 structural genes are either retained in the nucleus or degraded rapidly in the absence of Rev/RRE; therefore little protein can be expressed. Modifying HIV-1 genes is an excellent approach to circumvent this problem, but it is a laborious and costly process. Using certain vectors to deliver wild-type genes may be a promising approach. In this study, the wild-type and modified gag genes, derived from Chinese HIV-1 isolates, were separately constructed in both plasmid DNA and recombinant Sendai virus vectors (rSeV). The expression and immunogenicity of the wild-type and modified gag genes were compared. The results showed that efficient expression of the modified gag gene could be achieved by transfection with DNA and infection with rSeV, but the efficient expression of wild-type gag could only be achieved by rSeV. In addition, the rSeV expressing wild-type gag elicited similar Gagspecific immune responses with modified gag in both SeV/SeV and DNA-prime/rSeV-boost schemes. However, SeV/SeV failed to produce Gag-specific responses as robust as DNA/rSeV. Then the SeV-specific humoral and cellular immune responses were evaluated just before the second rSeV vaccine immunization. It was found that anti-SeV neutralizing antibody was very low but the SeV-specific cellular response was strong. Efficient expression of wild-type HIV-1 structural genes may make the SeV vector a useful tool for the HIV-1 vaccine research, but the strong SeV-specific cellular immune responses may impair the efficacy of SeV-SeV vaccination scheme.
Keywords: Sendai virus, HIV-1, gag gene, vaccine
Current HIV Research
Title: Comparison of the Expression and Immunogenicity of Wild-Type and Sequence-Modified HIV-1 gag Genes in a Recombinant Sendai Virus Vector
Volume: 8 Issue: 3
Author(s): Shuangqing Yu, Xia Feng, Tsugumine Shu, Tetsuro Matano, Mamoru Hasegawa, Xiaoli Wang, Hongxia Li, Zelin Li, Rugang Zhong and Yi Zeng
Affiliation:
Keywords: Sendai virus, HIV-1, gag gene, vaccine
Abstract: Efficient expression of HIV-1 structural gene involves regulation by viral Rev and Rev-responsive elements (RRE). Messenger RNAs of wild-type HIV-1 structural genes are either retained in the nucleus or degraded rapidly in the absence of Rev/RRE; therefore little protein can be expressed. Modifying HIV-1 genes is an excellent approach to circumvent this problem, but it is a laborious and costly process. Using certain vectors to deliver wild-type genes may be a promising approach. In this study, the wild-type and modified gag genes, derived from Chinese HIV-1 isolates, were separately constructed in both plasmid DNA and recombinant Sendai virus vectors (rSeV). The expression and immunogenicity of the wild-type and modified gag genes were compared. The results showed that efficient expression of the modified gag gene could be achieved by transfection with DNA and infection with rSeV, but the efficient expression of wild-type gag could only be achieved by rSeV. In addition, the rSeV expressing wild-type gag elicited similar Gagspecific immune responses with modified gag in both SeV/SeV and DNA-prime/rSeV-boost schemes. However, SeV/SeV failed to produce Gag-specific responses as robust as DNA/rSeV. Then the SeV-specific humoral and cellular immune responses were evaluated just before the second rSeV vaccine immunization. It was found that anti-SeV neutralizing antibody was very low but the SeV-specific cellular response was strong. Efficient expression of wild-type HIV-1 structural genes may make the SeV vector a useful tool for the HIV-1 vaccine research, but the strong SeV-specific cellular immune responses may impair the efficacy of SeV-SeV vaccination scheme.
Export Options
About this article
Cite this article as:
Yu Shuangqing, Feng Xia, Shu Tsugumine, Matano Tetsuro, Hasegawa Mamoru, Wang Xiaoli, Li Hongxia, Li Zelin, Zhong Rugang and Zeng Yi, Comparison of the Expression and Immunogenicity of Wild-Type and Sequence-Modified HIV-1 gag Genes in a Recombinant Sendai Virus Vector, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111133
DOI https://dx.doi.org/10.2174/157016210791111133 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Non-Invasive Delivery of iRNAs, Proteins, Peptides, Cytokines and Nanoparticles (Guest Editor: Bingmei M. Fu)]
Current Pharmaceutical Biotechnology Familial Mediterranean Fever in the Post-Genomic Era: How an Ancient Disease is Providing New Insights into Inflammatory Pathways
Current Drug Targets - Inflammation & Allergy Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury
Current Pharmaceutical Biotechnology Innate and Adaptive Immune Responses in Chronic HCV Infection
Current Drug Targets Interrelationships Between Cyclooxygenases and Aromatase: Unraveling the Relevance of Cyclooxygenase Inhibitors in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era
Current Medicinal Chemistry Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence
Current Psychiatry Reviews Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Biological and Anti-inflammatory Evaluation of Two Thiazole Compounds in RAW Cell Line: Potential Cyclooxygenase-2 Specific Inhibitors
Medicinal Chemistry Clinical Proteomics in Cancer Research
Current Proteomics The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Random Mutagenesis Methods for In Vitro Directed Enzyme Evolution
Current Protein & Peptide Science Radiation-Induced Bystander and other Non-Targeted Effects: Novel Intervention Points in Cancer Therapy?
Current Cancer Drug Targets Interaction of Wharton's Jelly Derived Fetal Mesenchymal Cells with Tumor Cells
Current Stem Cell Research & Therapy Patent Selections:
Recent Patents on Drug Delivery & Formulation Xanthine Oxidase and Transforming Growth Factor Beta-activated Kinase 1: Potential Targets for Gout Intervention
Current Rheumatology Reviews Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions
Current Medicinal Chemistry Evaluation of the Antidiabetic Property of Capparis Ovata Desf. Var. Palaestina Zoh. Extracts Using In vivo and In vitro Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets